GRFS – Grifols, S.A.
Float Short %
2.3
Margin Of Safety %
33
Put/Call OI Ratio
0.45
EPS Next Q Diff
EPS Last/This Y
0.76
EPS This/Next Y
0.32
Price
9.43
Target Price
11.52
Analyst Recom
3
Performance Q
-11.29
Relative Volume
1.54
Beta
0.68
Ticker: GRFS
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-10-06 | GRFS | 9.6 | 0.66 | 0.54 | 3079 |
| 2025-10-07 | GRFS | 9.58 | 0.66 | 999.99 | 3214 |
| 2025-10-08 | GRFS | 9.63 | 0.67 | 86.50 | 3231 |
| 2025-10-09 | GRFS | 9.49 | 0.79 | 0.00 | 3463 |
| 2025-10-10 | GRFS | 9.32 | 0.79 | 0.04 | 3468 |
| 2025-10-13 | GRFS | 9.46 | 0.77 | 0.45 | 3503 |
| 2025-10-14 | GRFS | 9.58 | 0.79 | 999.99 | 3522 |
| 2025-10-15 | GRFS | 9.6 | 0.79 | 999.99 | 3522 |
| 2025-10-16 | GRFS | 9.76 | 0.79 | 0.50 | 3522 |
| 2025-10-17 | GRFS | 9.65 | 0.79 | 131.00 | 3542 |
| 2025-10-20 | GRFS | 9.57 | 1.00 | 8.44 | 3727 |
| 2025-10-21 | GRFS | 9.34 | 1.02 | 0.00 | 3784 |
| 2025-10-22 | GRFS | 9.53 | 0.98 | 1.05 | 3874 |
| 2025-10-23 | GRFS | 9.56 | 0.97 | 0.00 | 3902 |
| 2025-10-24 | GRFS | 9.44 | 0.84 | 0.00 | 4205 |
| 2025-10-27 | GRFS | 9.37 | 0.70 | 0.01 | 4657 |
| 2025-10-28 | GRFS | 9.36 | 0.67 | 0.00 | 4813 |
| 2025-10-29 | GRFS | 9.38 | 0.55 | 0.00 | 5404 |
| 2025-10-30 | GRFS | 9.16 | 0.55 | 0.00 | 5408 |
| 2025-10-31 | GRFS | 9.36 | 0.48 | 0.60 | 5981 |
| 2025-11-03 | GRFS | 9.43 | 0.45 | 0.05 | 6502 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-10-06 | GRFS | 9.60 | - | - | 1.02 |
| 2025-10-07 | GRFS | 9.59 | - | - | 1.02 |
| 2025-10-08 | GRFS | 9.62 | - | - | 1.02 |
| 2025-10-09 | GRFS | 9.48 | - | - | 1.02 |
| 2025-10-10 | GRFS | 9.32 | - | - | 1.02 |
| 2025-10-13 | GRFS | 9.45 | - | - | 1.02 |
| 2025-10-14 | GRFS | 9.58 | - | - | 1.02 |
| 2025-10-15 | GRFS | 9.60 | - | - | 1.02 |
| 2025-10-16 | GRFS | 9.76 | - | - | 1.02 |
| 2025-10-17 | GRFS | 9.65 | - | - | 1.02 |
| 2025-10-20 | GRFS | 9.57 | - | - | 1.02 |
| 2025-10-21 | GRFS | 9.34 | - | - | 1.02 |
| 2025-10-22 | GRFS | 9.55 | - | - | 1.02 |
| 2025-10-23 | GRFS | 9.55 | - | - | 1.02 |
| 2025-10-24 | GRFS | 9.44 | - | - | 1.02 |
| 2025-10-27 | GRFS | 9.37 | - | - | 1.02 |
| 2025-10-28 | GRFS | 9.36 | - | - | 1.03 |
| 2025-10-29 | GRFS | 9.38 | - | - | 1.03 |
| 2025-10-30 | GRFS | 9.16 | - | - | 1.03 |
| 2025-10-31 | GRFS | 9.37 | - | - | 1.03 |
| 2025-11-03 | GRFS | 9.43 | - | - | 1.03 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-10-06 | GRFS | 0.00 | -0.12 | 2.08 |
| 2025-10-07 | GRFS | 0.00 | -0.12 | 2.08 |
| 2025-10-08 | GRFS | 0.00 | -0.12 | 2.08 |
| 2025-10-09 | GRFS | 0.00 | -0.12 | 2.08 |
| 2025-10-10 | GRFS | 0.00 | -0.12 | 2.37 |
| 2025-10-13 | GRFS | 0.00 | -0.09 | 2.37 |
| 2025-10-14 | GRFS | 0.00 | -0.09 | 2.37 |
| 2025-10-15 | GRFS | 0.00 | -0.09 | 2.37 |
| 2025-10-16 | GRFS | 0.00 | -0.09 | 2.37 |
| 2025-10-17 | GRFS | 0.00 | -0.09 | 2.37 |
| 2025-10-20 | GRFS | 0.00 | -0.06 | 2.37 |
| 2025-10-21 | GRFS | 0.00 | -0.06 | 2.37 |
| 2025-10-22 | GRFS | 0.00 | -0.06 | 2.37 |
| 2025-10-23 | GRFS | 0.00 | -0.06 | 2.37 |
| 2025-10-24 | GRFS | 0.00 | -0.06 | 2.37 |
| 2025-10-27 | GRFS | 0.00 | -0.45 | 2.30 |
| 2025-10-28 | GRFS | 0.00 | -0.45 | 2.30 |
| 2025-10-29 | GRFS | 0.00 | -0.45 | 2.30 |
| 2025-10-30 | GRFS | 0.00 | -0.45 | 2.30 |
| 2025-10-31 | GRFS | 0.00 | -0.45 | 2.30 |
| 2025-11-03 | GRFS | 0.00 | -0.80 | 2.30 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
Avg. EPS Est. Current Quarter
0.27
Avg. EPS Est. Next Quarter
0.36
Insider Transactions
Institutional Transactions
-0.8
Beta
0.68
Average Sales Estimate Current Quarter
1826
Average Sales Estimate Next Quarter
2021
Fair Value
12.56
Quality Score
60
Growth Score
91
Sentiment Score
64
Actual DrawDown %
54
Max Drawdown 5-Year %
-71.6
Target Price
11.52
P/E
19.67
Forward P/E
8.59
PEG
0.82
P/S
0.3
P/B
1.06
P/Free Cash Flow
2.68
EPS
0.48
Average EPS Est. Cur. Y
1.03
EPS Next Y. (Est.)
1.35
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
4.02
Relative Volume
1.54
Return on Equity vs Sector %
-20
Return on Equity vs Industry %
-30.7
EPS 1 7Days Diff
EPS 1 30Days Diff
EBIT Estimation
Grifols, S.A.Sector: Healthcare
Industry: Drug Manufacturers - General
Employees: 23833
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma, and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factor VIII/von Willebrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It also markets diagnostic testing equipment, reagents, and other equipment; offers biological products and manufacturing services; and manufactures and sells plasma to third parties. In addition, the company offers Yimmugo IDP, an immunology drug; Yimmugo PTI, a hematology drug; and Prolastin vials, a pulmonology drug. Further, it develops Xembify Pre-filled syringes, Gamunex Bags, and FlexBag; Xembify Biweekly dosing, Fibrinogen, and VISTASEAL; Prolastin-C AADT and Fostamatinib; Xembify CLL, Albumina 20% and 5%, and Trimodulin; Alfa-1 AT 15%, GRF6019, GRF6021, Aßvac402, AKST4290, and AKST4290; GIGA 2339 and GIGA564; and recIG, Alfa-1 AT - in non-cystic fibrosis bronchiectasis, and OSIG that are in pre-clinical stage. It has collaboration agreements with Canadian Blood Services to supply grains of Immunoglobulin. The company was founded in 1909 and is headquartered in Barcelona, Spain.
stock quote shares GRFS – Grifols, S.A. Stock Price stock today
news today GRFS – Grifols, S.A. stock forecast ,stock prediction 2023 2024 2025
marketwatch GRFS – Grifols, S.A. yahoo finance google finance
stock history GRFS – Grifols, S.A. invest stock market
stock prices GRFS premarket after hours
ticker GRFS fair value insiders trading